Astrazeneca (AZN) Cost of Revenue (2009 - 2026)

Astrazeneca's Cost of Revenue history runs 18 years deep, the most recent figure standing at $2.7 billion for Q1 2026.

• In Q1 2026, Cost of Revenue rose 19.5% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $11.1 billion (up 8.21% YoY), while the FY2025 annual figure was $10.6 billion, up 4.17% from the prior year.
• Cost of Revenue was $2.7 billion for Q1 2026 at Astrazeneca, down from $3.1 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $3.5 billion in Q1 2022 to a low of $1.9 billion in Q1 2023.
• Historically, Cost of Revenue has averaged $2.6 billion across 5 years, with a median of $2.7 billion in 2026.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue surged 138.4% in 2022, then plunged 45.74% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $2.9 billion in 2022, then retreated by 20.41% to $2.3 billion in 2023, then advanced by 18.07% to $2.7 billion in 2024, then increased by 14.42% to $3.1 billion in 2025, then declined by 14.11% to $2.7 billion in 2026.
• The last three Cost of Revenue figures came in at $2.7 billion (Q1 2026), $3.1 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.